Valuation of the use of biomarkers predictive of drug efficacy to enrich responders in oncology drug clinical development
Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology; and, (S.M.)--Massachusetts Institute of Technology, Sloan School of Management, 2006.
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Language: | eng |
| Published: |
Massachusetts Institute of Technology
2007
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1721.1/35679 |
| _version_ | 1811088773722669056 |
|---|---|
| author | Wine, David |
| author2 | A. Gregory Sorensen and Teodro Forcht Dagi. |
| author_facet | A. Gregory Sorensen and Teodro Forcht Dagi. Wine, David |
| author_sort | Wine, David |
| collection | MIT |
| description | Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology; and, (S.M.)--Massachusetts Institute of Technology, Sloan School of Management, 2006. |
| first_indexed | 2024-09-23T14:07:20Z |
| format | Thesis |
| id | mit-1721.1/35679 |
| institution | Massachusetts Institute of Technology |
| language | eng |
| last_indexed | 2024-09-23T14:07:20Z |
| publishDate | 2007 |
| publisher | Massachusetts Institute of Technology |
| record_format | dspace |
| spelling | mit-1721.1/356792019-04-12T12:37:34Z Valuation of the use of biomarkers predictive of drug efficacy to enrich responders in oncology drug clinical development Wine, David A. Gregory Sorensen and Teodro Forcht Dagi. Sloan School of Management. Harvard University--MIT Division of Health Sciences and Technology. Sloan School of Management. Harvard University--MIT Division of Health Sciences and Technology. Sloan School of Management. Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology; and, (S.M.)--Massachusetts Institute of Technology, Sloan School of Management, 2006. Includes bibliographical references (leaves 57-59). I study several aspects of the value in performing oncology clinical trials using screening biomarkers to preferentially select and enroll responders. From trial reports and investigational reports on potential biomarkers, I construct a series of six cases comparing the trial as conducted to a hypothetical trial using different screening and eligibility criteria. These cases illustrate, within limits of the model, what difference the use of a plausible biomarker test may have on trial size, cost, number of patients screened, and number of patients exposed to experimental treatment without benefit. by David Wine. S.M. 2007-01-10T17:01:23Z 2007-01-10T17:01:23Z 2006 2006 Thesis http://hdl.handle.net/1721.1/35679 76838462 eng M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. http://dspace.mit.edu/handle/1721.1/7582 58 leaves 2697725 bytes 2700104 bytes application/pdf application/pdf application/pdf Massachusetts Institute of Technology |
| spellingShingle | Harvard University--MIT Division of Health Sciences and Technology. Sloan School of Management. Wine, David Valuation of the use of biomarkers predictive of drug efficacy to enrich responders in oncology drug clinical development |
| title | Valuation of the use of biomarkers predictive of drug efficacy to enrich responders in oncology drug clinical development |
| title_full | Valuation of the use of biomarkers predictive of drug efficacy to enrich responders in oncology drug clinical development |
| title_fullStr | Valuation of the use of biomarkers predictive of drug efficacy to enrich responders in oncology drug clinical development |
| title_full_unstemmed | Valuation of the use of biomarkers predictive of drug efficacy to enrich responders in oncology drug clinical development |
| title_short | Valuation of the use of biomarkers predictive of drug efficacy to enrich responders in oncology drug clinical development |
| title_sort | valuation of the use of biomarkers predictive of drug efficacy to enrich responders in oncology drug clinical development |
| topic | Harvard University--MIT Division of Health Sciences and Technology. Sloan School of Management. |
| url | http://hdl.handle.net/1721.1/35679 |
| work_keys_str_mv | AT winedavid valuationoftheuseofbiomarkerspredictiveofdrugefficacytoenrichrespondersinoncologydrugclinicaldevelopment |